IRulya Therapeutics Inc. (IRLA) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, IRulya Therapeutics Inc. (NASDAQ: IRLA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $33.55 (+1.82% 1D, market cap $357.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IRLA ranks #626 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IRLA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FENC (Fennec Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -25.9%, cap $358.7M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $350.7M). Among the 5-stock peer group, IRLA leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).
Per IRLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662774), IRulya Therapeutics Inc. generated $162.6M in revenue (+1.4% YoY), -$84.0M in net income, and -$41.8M in free cash flow against $93.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IRLA currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($31.01) and Max Pain ($35.23) forces dealer call-delta covering toward $955.50.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
IRulya Therapeutics Inc. (IRLA) advanced +1.82% to $33.55, trading at 2% of its 52-week range ($15.1 – $910). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Fierce Pharma report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC) shares rose
NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious unde
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IRLA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IRLA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, IRulya Therapeutics Inc. (IRLA) ranks #626 by composite RQD confidence (34/100, grade E) and #491 by equity capitalization ($357.2M). Within this direct 5-issuer industry benchmark cohort, IRLA leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with IRLA at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IRLA
ACTIVE
IRulya Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +1.82% | $357.2M | Benchmark Subject |
| FENC Fennec Pharmaceuticals Inc. | E | 33/100 | — | — | -25.9% | +2.93% | $358.7M | /fenc-vs-irla → |
| KYTX Kyverna Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -7.94% | $350.7M | /kytx-vs-irla → |
| AGMB AgomAb Therapeutics NV | D | 45/100 | — | — | — | -10.28% | $368.9M | /agmb-vs-irla → |
| TRXB TRex Bio Inc. | D | 48/100 | — | — | — | -0.73% | $377.1M | /trxb-vs-irla → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), IRulya Therapeutics Inc. (IRLA) reported GAAP revenue of $162.6M (+1.4% vs. FY2024 revenue of $160.4M , and +67.7% cumulative change since FY2023) , GAAP net income of -$84.0M, operating cash flow of -$41.4M, and free cash flow of -$41.8M (-29.9% YoY). On the balance sheet, IRLA closed FY2025 with $93.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $162.6M | -$84.0M | -$41.4M | -$41.8M | $93.5M | — |
| FY2024 (FY) | 2024-12-31 | $160.4M | -$56.8M | -$31.9M | -$32.2M | $114.5M | — |
| FY2023 (FY) | 2023-12-31 | $96.9M | -$31.4M | -$18.3M | -$18.3M | — | — |
As of 2026-11-03, IRulya Therapeutics Inc. (NASDAQ: IRLA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $33.55 (+1.82% 1D, market cap $357.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IRLA ranks #626 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IRLA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FENC (Fennec Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -25.9%, cap $358.7M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $350.7M). Among the 5-stock peer group, IRLA leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).
Per IRLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662774), IRulya Therapeutics Inc. generated $162.6M in revenue (+1.4% YoY), -$84.0M in net income, and -$41.8M in free cash flow against $93.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
IRLA last traded at $33.55 (+1.82% on volume of 96,493 shares), positioning the stock +8.19% above its 50-day simple moving average ($31.01) and -30.62% below its 200-day simple moving average ($48.36). Across its 52-week range of $15.10 to $910.00, IRLA sits at the 2.1% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($29.36 to $37.74).
IRulya Therapeutics Inc. (IRLA) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $33.55 (+1.82% 1D, market capitalization $357.2M).
IRulya Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..3B. Per the recent news wire, the company was formerly known as Quince Therapeutics and has repositioned toward pulmonary and lung disease drug development.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IRulya Therapeutics Inc. (IRLA) reported $162.6M in annual revenue (up from $160.4M in FY2024, +1.4% YoY) and -$84.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($96.9M revenue, -$31.4M net income) through FY2025, IRLA scaled operating cash flow to -$41.4M and free cash flow to -$41.8M, backed by $93.5M in total assets against $0 in total debt.
The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations for IRLA beyond the sector and industry classification.
Real-time company headlines, analyst actions, and sector developments for IRulya Therapeutics Inc. (IRLA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Fierce Pharma report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering IRulya Therapeutics Inc. (IRLA) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating IRulya Therapeutics Inc. (IRLA). The Roarable RQD rating records a Debt/Equity ratio of 0.5, indicating modest leverage relative to equity.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $35.59.
Both sides have a point here — IRLA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
The company reports zero revenue, FY 2025 net loss of -$84.0M, and free cash flow of -$41.8M against only $5.8M in cash.. Look at the math on IRLA: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $29.00 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).